What guidance did Codexis's management provide for the next earnings period?

What is the market's earnings forecast for Codexis next quarter?

What were the key takeaways from Codexis's earnings call?

Did Codexis beat or miss consensus estimates last quarter?

What were the key takeaways from Codexis’s earnings call?

What is Codexis's latest dividend and current dividend yield?

What factors drove the changes in Codexis's revenue and profit?

What does Codexis do and what are its main business segments?

- **Strategic Shift Confirmed**: Transition to manufacturing partner with Merck deal and new facility, reducing legacy enzyme focus.
- **Financial Resilience**: $58.7M cash (pre-Merck) with 25% burn reduction, extending runway to 2027.
- **Pipeline Momentum**: 11 active contracts, 40 in pipeline, and 14 Phase III drugs leveraging enzyme tech.
- **Operational Excellence**: 64% gross margin, cost controls driving efficiency improvements.
- **Upcoming Catalysts**: TIDES EU presentations on scalability and analytics, Q1 2026 guidance update.

**【CEO Summary Section】**
- Signed a supply assurance agreement with Merck, providing nondilutive cash to support business plans.
- Leasing a new GMP facility for kilogram-scale siRNA manufacturing using ECO Synthesis.
- Transitioning from enzyme supplier to full-service manufacturing partner, with 11 revenue-generating contracts and 40 in pipeline.
- Leadership transition: Alison Moore becomes CEO, Stephen Dilly remains Executive Chair.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $8.6 million (down 33% YoY) due to legacy business decline.
- Gross margin: 64% (up 3% YoY) from shift to more profitable products.
- R&D expenses: $13.9 million (up 21% YoY) due to headcount and reclassification.
- SG&A expenses: $11.2 million (down 18% YoY) from cost reductions.
- Net loss: $19.6 million, cash position: $58.7 million (excluding Merck funds).
- Restructuring reduces burn by 25%, extending cash runway to 2027.

**【Q&A Key Highlights】**
- **Partnership Strategy**: Maintaining flexibility with Nitto Avecia for scaling, while exploring direct manufacturing and royalty-based models.
- **Revenue Contribution**: Service revenue expected to remain stable, with siRNA contracts in service segment.
- **TIDES EU Presentations**: Focus on platform scalability and in-process analytics, positioning as first-in-class for siRNA developers.
- **Legacy Business**: 14 drugs in Phase III using Codexis enzymes, providing long-term growth potential despite reduced focus.
- **Cash Outlook**: Merck funds to be recognized in Q4 2025 and Q1 2026, supporting 2026 guidance release post-year end.

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q2 2025 revenue up 91% YoY to $15.3M, driven by ECO Synthesis and Pharma Biocatalysis.
- **ECO Platform Demand Soars**: Over 30 customer engagements, with new ligase customers expected Q4.
- **Gross Margin Expansion**: 72% in Q2 2025 vs. 45% YoY, reflecting shift to high-margin products.
- **Cash Position Strong**: $66.3M cash, sufficient for operations through Q1 2027.
- **Strategic Focus**: ECO Synthesis expansion prioritized over short-term breakeven.

**【CEO Summary Section】**
- Q2 2025 revenue of $15.3M exceeded expectations, up 91% YoY, driven by Pharma Biocatalysis and ECO Synthesis growth.
- ECO Synthesis demand outpaces supply, with over 30 customer engagements and new ligase customers expected by year-end.
- Targeting cash flow breakeven by end-2026, but prioritizing ECO platform expansion to maximize long-term returns.
- Gross margin improved to 72% (Q2 2025) from 45% (Q2 2024), reflecting shift to higher-margin products.

**【COO Summary Section】**
- Pharma Biocatalysis remains the cash cow, with late-stage API orders fueling 15%+ CAGR.
- ECO Synthesis lab utilization near capacity, with 3+ new ligase customers in pipeline.
- GMP facility expansion under consideration to service small/mid biotechs directly, reducing reliance on CDMOs.
- Ligase library performance differentiates Codexis, winning back customers from competitors.

**【CFO Financial Commentary】**
- Q2 2025: 
  - Revenue: $15.3M (vs. $8M YoY)
  - Gross Margin: 72% (vs. 45% YoY)
  - R&D: $13.8M (vs. $11.4M YoY)
  - SG&A: $12.4M (vs. $15.7M YoY)
  - Net Loss: $13.3M (vs. $23.8M YoY)
- Cash balance: $66.3M, sufficient to fund operations through Q1 2027.
- 2025 guidance reaffirmed: $64-68M revenue.

**【Q&A Highlights】**
- Pipeline growth: 30+ ECO Synthesis discussions (mix of CDMOs, pharma, stealth biotechs)
- ECO Lab #2 expansion underway to handle demand
- GMP strategy: Codexis-owned facility vs. CDMO partnerships
- IP strategy: Trade secrets + patents protect ECO platform
- Revenue visibility: Q4 typically strongest, with ECO Synthesis driving H2 growth

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

- **Q1 Execution Strong**: Revenue aligns with expectations, 2025 guidance reaffirmed with H2 ramp driven by ECO platform adoption.
- **ECO Platform Differentiation**: 5x larger batches, 70% lower CapEx, and chirality control enable siRNA manufacturing at scale.
- **CDMO Traction**: Three CDMOs successfully replicated Codexis Ligase performance in-house, validating technology transferability.
- **Cash Position Secure**: $59.8 million cash runway supports 2026 cash flow positivity target.
- **AI Acceleration**: Machine learning reduces ligase development time by 50%, with manufacturing applications in development.


**【CEO Summary Section】**
- Q1 2025 revenue of $7.5 million aligns with expectations, driven by delayed $2.5 million Pharma Biocatalysis payment. 2025 guidance of $64-68 million remains unchanged, with H2 revenue ramp expected.
- Pharma Biocatalysis business sees margin improvement and new mid-tier pharma customers. ECO platform progress includes first revenue-generating contract and Ligase orders from large Pharma and CDMO partners.
- Ecosynthesis platform advantages: 5x larger batch sizes, 50% faster setup, 70% lower CapEx vs. chemical synthesis. TIDES USA presentations will showcase scalability, chirality control, and machine learning-driven ligase optimization.

**【CFO Financial Commentary】**
- Q1 2025 product gross margin improved to 55% (vs. 49% Q1 2024) due to higher-margin product mix.
- R&D expenses rose 15% to $12.9 million, driven by salary and lab costs. SG&A decreased 4% to $12.4 million due to lower legal fees.
- Cash position remains strong at $59.8 million, supporting operations through 2026 cash flow positivity target.

**【Q&A Key Takeaways】**
- **Customer Segment Strategy**: CDMOs are early adopters due to their need to scale manufacturing. Small drug innovators are cash-constrained, while large innovators await proof of concept. CDMO partnerships (e.g., Bachem) are key to funneling drug innovator customers.
- **Order Growth**: Large Pharma Ligase orders expected to repeat annually, scaling from grams to hundreds of grams. CDMO adoption will accelerate with TIDES presentations.
- **GMP Facility Timing**: Investment in Codexis-owned GMP facility will be data-driven, contingent on order flow. Current plan: incremental spending through 2026, with validation in 2027.
- **Machine Learning Impact**: Ligase selection tool reduces process development time by 50%, lowering customer costs. AI integration into manufacturing will further optimize scalability.


Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

- **Revenue Growth Momentum**: 15% YoY growth in Q4 2024, driven by pharma biocatalysis recovery and ECO platform maturation.
- **ECO Platform Breakthrough**: Completed first full-scale enzymatic synthesis of a commercial siRNA drug, with 7+ active customer engagements in 2025.
- **Financial Discipline**: 2025 revenue guidance of $64-68 million reflects double-digit growth across all business segments, supported by $73.5 million in cash reserves.
- **Strategic Partnerships**: New Pfizer agreement expands enzyme supply beyond PAXLOVID, while GMP scale-up partnerships will accelerate clinical timelines.
- **Gross Margin Improvement**: 2025 initiatives target ongoing margin expansion through product mix optimization and low-margin divestitures.

**【CEO Summary Section】**
- Codexis achieved a 15% YoY revenue growth in Q4 2024, driven by the recovery of its pharma biocatalysis business and the maturation of its enzymatic siRNA synthesis (ECO) platform.
- The company emphasized its strategic focus on reducing costs, strengthening the balance sheet, and advancing its ECO Synthesis platform, which completed its first full-scale enzymatic synthesis of a commercial siRNA drug in 2024.
- Key 2025 milestones include signing a GMP scale-up partnership, completing pilot-scale GLP production in the ECO Innovation Lab, and securing raw material supply chains.

**【CFO Financial Commentary】**
- Q4 2024 total revenue was $21.5 million, with product revenue of $9.8 million and R&D revenue of $11.6 million. Excluding the Pfizer PAXLOVID partnership, annual revenue was $59.3 million, reflecting a transition year for the business.
- Gross margin for the year was 56%, down from 66% in 2023, primarily due to product mix changes. The company expects ongoing improvements in gross margins through divestiture of lower-margin products.
- 2025 revenue guidance is $64 million to $68 million, with a focus on double-digit growth across the entire business base, driven by the ligase and ECO Synthesis platforms.
- Cash reserves of $73.5 million at year-end are sufficient to fund operations through achieving cash flow positivity by 2026.

**【COO Operational Update】**
- 2025 will mark the commercial launch of the ECO Synthesis platform, with 7+ active customer engagements across ligation services, sequential synthesis, and full ECO development.
- The company completed feasibility studies with multiple leading siRNA innovators, demonstrating the platform's ability to improve purity and yield in siRNA manufacturing.
- Strategic initiatives include expanding mid-tier pharma partnerships, leveraging the ECO toolbox for diverse customer needs, and establishing a full-service GMP facility to support small innovators.

**【Q&A Highlights】**
- **Partnership Confidentiality**: Large pharma partners prioritize confidentiality, requiring Codexis to balance transparency with customer trust (e.g., removing partner logos 48 hours before public presentations).
- **Gross Margin Improvement**: 2025 efforts focus on retiring low-margin products and optimizing product mix, with annual gross margin improvements expected.
- **GMP Facility Investment**: A GMP scale-up partnership will accelerate clinical supply timelines, while plans for a company-owned facility are in the planning phase with capital costs to be disclosed in 2025.
- **Pfizer Collaboration**: The new long-term agreement expands beyond PAXLOVID to include enzyme supply for Pfizer's pipeline drugs, reflecting Codexis' strategic position in pharma biocatalysis.
- **Small Innovator Strategy**: Codexis offers upfront payments for CMC development in exchange for back-end royalties, addressing the capital constraints of rare disease drug developers.

Codexis (CDXS)-27 Feb 25-2024 Q4 Earnings call transcript

Codexis (CDXS)-31 Oct 24-2024 Q3 Earnings call transcript

Codexis (CDXS)-8 Aug 24-2024 Q2 Earnings call transcript

Codexis (CDXS)-2 May 24-2024 Q1 Earnings call transcript

Codexis (CDXS)-28 Feb 24-2023 Q4 Earnings call transcript

- **Financial Strength**: $74.6 million cash balance, 50%+ cash burn reduction, and 2026 positive cash flow target.
- **ECO Synthesis Milestones**: Gram-scale synthesis by year-end, customer testing in H1 2024, and commercial launches in 2025-2026.
- **Pharma Growth**: 2024 revenue expected to return to growth, driven by pipeline products and normalized orders.
- **Strategic Moves**: Formation of SAB with John Maraganore to accelerate ECO Synthesis adoption; exploring asset monetization deals.

**【CEO Summary Section】**
- Codexis ended Q3 2023 with a strong financial position, including $74.6 million in cash, driven by a $135 million windfall from CDX-616 sales to Pfizer.
- The company reduced annual cash burn by over 50%, targeting $20-30 million annually, and expects positive cash flow by late 2026.
- The ECO Synthesis platform is advancing toward gram-scale synthesis by year-end, with plans for customer testing in H1 2024 and commercial launches in 2025-2026.
- A strategic advisory board, including John Maraganore (Alnylam co-founder), was formed to guide ECO Synthesis commercialization.

**【CFO Financial Commentary】**
- Q3 2023 product revenue (excluding Paxlovid) was $9.3 million, down 56% YoY due to timing of customer orders, but Q4 is expected to normalize.
- R&D revenue declined 39% YoY to $3.9 million, reflecting wind-down of biotherapeutics programs.
- Product gross margin (ex-Paxlovid) was 58%, within the 55-65% guidance range.
- GAAP net loss was $12.3 million, including one-time charges of $13.1 million for restructuring and asset impairments.

**【Q&A Key Highlights】**
- **ECO Synthesis Progress**: Demonstrated improved coupling efficiency and longer RNA strands at TIDES Europe, with gram-scale synthesis expected by year-end.
- **Customer Engagement**: CDMOs expressed interest in enzymatic solutions to reduce capital costs, with potential orders for double-stranded RNA ligase in H2 2024.
- **Pharma Manufacturing Growth**: 2024 revenue growth will come from pipeline products and normalized ordering patterns, with $30-35 million full-year guidance maintained.
- **Paxlovid Accounting**: $8 million non-cash revenue in Q4 2023 and $9 million in Q4 2024, completing retainer fee recognition.
- **Partnerships**: Exploring collaborations to monetize life sciences assets, with potential deals by end-2023.

CDXS

CDXS fundamentals

Earnings Call

You can ask Aime